Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.
about
Hepatitis C virus replication is modulated by the interaction of nonstructural protein NS5B and fatty acid synthaseHuman monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzeesQuantitative Proteomics Analysis of the Hepatitis C Virus Replicon High-Permissive and Low-Permissive Cell LinesHepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.The missing pieces of the HCV entry puzzle.Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.Human apolipoprotein A-I is associated with dengue virus and enhances virus infection through SR-BI.Syndecan 4 is involved in mediating HCV entry through interaction with lipoviral particle-associated apolipoprotein EUnderstanding Dengue Virus Capsid Protein Interaction with Key Biological TargetsLiver-targeted antiviral peptide nanocomplexes as potential anti-HCV therapeuticsApolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C VirusDiscovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection.CD36 is a co-receptor for hepatitis C virus E1 protein attachment.Very-low-density lipoprotein (VLDL)-producing and hepatitis C virus-replicating HepG2 cells secrete no more lipoviroparticles than VLDL-deficient Huh7.5 cells.A human apolipoprotein E mimetic peptide reduces atherosclerosis in aged apolipoprotein E null mice.Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virusLipids and HCV.Low density lipopolyprotein inhibits flavivirus acquisition in Aedes aegypti.Liver cell-targeted delivery of therapeutic molecules.Extracellular Interactions between Hepatitis C Virus and Secreted Apolipoprotein E.Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission.Extracellular lipid-free apolipoprotein E inhibits HCV replication and induces ABCG1-dependent cholesterol efflux.Apolipoprotein E mediates attachment of clinical hepatitis C virus to hepatocytes by binding to cell surface heparan sulfate proteoglycan receptorsSyndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytes.Hepatitis C virus-apolipoprotein interactions: molecular mechanisms and clinical impact.Neglected but Important Role of Apolipoprotein E Exchange in Hepatitis C Virus Infection.Analogs of LDL Receptor Ligand Motifs in Dengue Envelope and Capsid Proteins as Potential Codes for Cell Entry.Repurposing an old drug: A low-cost allergy medication provides new hope for hepatitis C patients.Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.Hepatitis C Virus (HCV)-Apolipoprotein Interactions and Immune Evasion and Their Impact on HCV Vaccine Design.
P2860
Q24318935-382C1591-751F-4BB9-939C-62B6CE74AEBFQ28483065-EC5415F2-3695-443D-973C-421E59BA04F2Q28550751-7E94F4CC-2350-4343-95B5-A2B20DA42F06Q30386551-8B0CEBE9-4E96-4287-83B8-942104F0C6C0Q33360674-18124D1C-F8A3-4AE6-9AB4-86531072B602Q34470890-4C8319BC-5099-4F75-8B60-CB5B63BFDA0DQ34876325-9513CC0A-5594-43BA-BA9C-5FE93B442446Q35153978-86907869-52E4-4713-A760-2142FA22A02AQ35838079-E99AE065-5C91-4D79-9FA9-E867F3EFDE81Q36035550-9F7177EF-C55C-4A9E-94F4-4FB59C77D929Q36080826-99CCE375-C5C8-4D06-AB85-99FABB230FCEQ36579835-383CA8AD-6DCE-4C6C-B7D3-D5AF2B4620AAQ36602246-D13F4242-2BDD-457C-BF42-BE37C8E296ECQ36760026-50F4A374-01C6-40A7-B4C1-6341B2CA49A1Q37228000-CD3BAB94-A079-4E0A-8478-0E66F35FE0CDQ37336742-2870902E-8DAA-487D-B698-36C7CE2BAAE6Q37547255-42DCB42F-40F1-4BD2-9727-4F160C6BC2EFQ38056643-C307B464-5033-4C21-82AA-76C7DDC4D1B0Q38157698-EBF7522B-A866-4ACF-B2D8-09FCE40502A7Q38229624-EAA26488-ECDD-4D76-BBF0-66B2C8221D8AQ38702378-0C9C3F0F-9220-488E-8BF5-DF943C6C29E3Q38707908-01046BC4-04EC-41CF-83CC-59AE6E1C0F21Q38747495-7EBC8FD7-0B87-4657-8161-A19D53492D48Q39127434-E3ADF7B4-48E7-4010-8405-BAC380F9743FQ39168236-B88EDE54-1978-4264-9888-69293F3FE12AQ39380623-D318B685-7722-4544-B6AB-5833DF006DF7Q39480497-AB51A1A9-0460-42AE-B6B7-D6E6A80A750AQ40175804-46FE35D6-9BA0-48D5-9319-F39CD4B6F3D4Q41073659-4DABB0EB-E8F0-4269-992E-7C110E6A77E4Q41564973-5A5663FC-D91D-4AB4-B5C2-C6424332719DQ55513556-9C2C49F3-0B40-4E82-A1C7-B6A4535000F2
P2860
Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Human apolipoprotein E peptide ...... try by blocking virus binding.
@en
type
label
Human apolipoprotein E peptide ...... try by blocking virus binding.
@en
prefLabel
Human apolipoprotein E peptide ...... try by blocking virus binding.
@en
P2093
P2860
P356
P1433
P1476
Human apolipoprotein E peptide ...... try by blocking virus binding.
@en
P2093
Daping Fan
Kevin D McCormick
Shufeng Liu
Tianyi Wang
Wentao Zhao
P2860
P304
P356
10.1002/HEP.25665
P407
P577
2012-07-02T00:00:00Z